Professor Shen Yang's new achievements of ovarian cancer treatment of ovarian cancer was published in the world -renowned journal

Recently, Professor Shen Yang, deputy dean of the University of Southeast University, Professor Shen Yang, a well -known obstetrics and gynecology expert, and the research results of the research results of Professor Liang Gaolin, School of Biological Science and Medical Engineering, Southeast University, published online in the international famous academic journal "AdvancedScience". ("Advanced Science", the latest influence is 16.806). Professor Shen Yang, Professor Liang Gaolin, and Dr. Zhan Wenjun of Southeast University are the author of the joint communication.

The research title is "SALT-Incible Kinase 2-Triggered Release of ITS Inhibitor from Hydrogel to Suppress Ovarian Cancer Metastasis", which reasonably designed a sensitive gel factor with SIK2 inhibitory HG-9 (SIK2) sensitive gel factor HG-9 (Sik2). -91-01 (HG) assembled a super molecular hydrogel, realizing the response release of HG in the ovarian tumor site (ADV. SCI., 2022, 2202260). The study was funded by the National Natural Science Foundation of China, the research project of the Jiangsu Provincial Health and Health Commission, and the key research and development plan of Jiangsu Province.

According to reports, ovarian cancer is the third largest and most fatal gynecological malignant tumor. It develops rapidly. In the early stages of no obvious symptoms, most ovarian cancer can only be diagnosed in the late stage. At present, the preferred treatment plan for ovarian cancer is surgery and chemotherapy. However, after the first -line chemotherapy plan, 75%of patients still relapse.

Salladase 2 (SIK2) is a lingine/sourein protein kinase, which belongs to the AMPK -based AMPK) family. In recent years, it is considered a very attractive and potential treatment target. Studies have shown that SIK2 is expressed in both primary ovarian cancer tissue and metastases, which plays a vital role in the occurrence and progress of tumors. Currently commonly used SIK inhibitors ARN-3236, YKL-05-099, YKL 06-061 and HG-9-91-01 (HG) have a good inhibitory effect on SIK2's activity inhibitory. The family members show the best selectivity to SIKS. In vitro experiments, HG successfully inhibited ovarian cancer metastasis by targeting ATP binding sites and a small water sac near the site. However, in the body experiments, HG's biological utilization is low, the plasma half -life, and the cytotoxicity that cannot be ignored, which greatly reduces its treatment effect and is not suitable for direct administration.

Professor Shen Yang introduced that the innovation point of the research lies in designing a salt -induced kinase 2 response hydrogel. The super molecular hydrogel material can use the enzymes that are excessively expressed in ovarian cancer tissue/cells as a stimulating response. Induced it with decomposition degradation to release drugs in response. The gel factor of the super molecular hydrogel is simple and the structure is clear and controllable. At the same time, it can be used to cool-cooling to form a self-assembly to form a super molecular hydrogel to achieve a stable high load of the drug.

It is understood that the use of super molecular hydraulic wrap drugs for disease treatment has been widely used. However, the hydrogels of enzyme Sik2 responded to the highly expression of ovarian cancer, or the hydrogels of the wrapping Sik2 inhibitor have not yet been reported. Professor Shen Yang's research group and Professor Liang Gaolin designed a gel factor that responded to Sik2. Under the induction of SIK2, the gel factor is propagated by phosphorylation and hydrogels to be assembled and slowly released the SIK2 inhibitor HG-9-91-01, which significantly improves the inhibitory effect of HG on ovarian cancer cells. Animal experiment results show that the enzyme -nordy -type super molecular hydrogel significantly improves the inhibitory effect of inhibitors on ovarian cancer. This "intelligent" strategy inspires people to design new pre -pharmaceutical molecules for cancer synergistic treatment, and improves the safety of treatment while increasing efficacy. (Liu Mincheng Shouqin)

- END -